All News
Scleroderma-associated Interstitial Lung Disease
While we know there are certain clinical features serving as predictors that patients with SSc may develop ILD, including diffuse skin disease and serologies such as anti-Scl-70 and Th/To antibodies, it is imperative that clinicians consider that any patient, particularly early in their disease course (5 years of disease since the first non-Raynaud phenomenon symptom) could develop ILD.
Read Article
GLP-1 Drugs Reduce Rheumatoid Arthritis Symptoms
Patients with rheumatoid arthritis (RA) who used GLP-1 receptor agonists had less disease activity and improved cardiovascular biomarkers, a small retrospective study indicated.
https://t.co/x2soZxuZCO https://t.co/84lnQOzsvP
Dr. John Cush RheumNow ( View Tweet)
What you need to know about scleroderma-related lung fibrosis
What do you need to know about scleroderma-related lung fibrosis as a practicing rheumatologist?
https://t.co/Ezl5G5IZeI https://t.co/zTF4lIYCAJ
Dr. John Cush RheumNow ( View Tweet)
Guselkumab (Tremfya) 1st IL-23 inhibitor to be FDA approved for subcutaneous induction in adults with ulcerative colitis https://t.co/KaZVzyomeY
Dr. John Cush RheumNow ( View Tweet)
New Multidisciplinary Classification of the Interstitial Pneumonias: ATS/ERS Guideline.
https://t.co/HWteOikGXT
🫁🩻🎞⚔️🐍🧪🔬💡📚
@ERSpublications @EuroRespSoc @ALATorax @SPLF_SocPneumo @pneumosbpt @NeumoMadrid @SeparRespira @HUReinaSofia @neumoparatodos @Neumosur @NeumoNat https://t.co/GnJjuxMIEm
Links:
jpedrokessner KessnerJp ( View Tweet)
Verba Volant, Scripta Manet
- Latin proverb meaning "spoken words fly away, written words remain", https://t.co/gXgDR7YS0C
Dr. John Cush RheumNow ( View Tweet)
Join us Sept 23 @ 7PM ET for the next Rheum to Breathe Journal Club!
We’ll dive into two pivotal ILD studies:
📄 FIBRONEER (Nerandomilast in PPF) – NEJM 2025
📄 RECITAL (Rituximab vs Cyclophosphamide in CTD-ILD) – Lancet
Panelists: Dr. Toby Maher, Dr. Shervin Assassi
Moderator: https://t.co/BebFhDJ1mM
Dr. John Cush RheumNow ( View Tweet)
Equal Safety of JAK Inhibitors and TNF Inhibitors
JAMA has published a systematic review and meta-analysis of head-to-head studies showing there was no meaningful difference in safety events observed when taking either JAK inhibitor (JAKi) vs TNF antagonist (TNFi) therapies for https://t.co/DTux5QdETS
Dr. John Cush RheumNow ( View Tweet)
When Myositis Hits the Lungs: What Every Rheumatologist Should Know About ILD
When idiopathic inflammatory myopathies (IIM) affect the lungs, the consequences can be serious. Interstitial lung disease (ILD) is not only common in IIM, but also one of the leading causes of death, https://t.co/Kxbarq9tiD
Dr. John Cush RheumNow ( View Tweet)
STOP-RA: Hydroxychloroquine Fails in ACPA+ Arthralgia
Deane et al has published the results of the STOP-RA trial, demonstrating that 12 months of hydroxychloroquine (HCQ) did not prevent the development of clinical RA at 36 months.
https://t.co/wsnc9uZi1P https://t.co/MwZJAQs7Rt
Dr. John Cush RheumNow ( View Tweet)
🆕 ILD (Part II): advanced insights
🫁 Multidisciplinary management
💊 Treatment strategies
📊 Prognosis & monitoring
🧑⚕️ What rheums should know next
⬇️ Download & learn more: https://t.co/XNmbcfqKKF
Created by
@MithuRheum | For our Rheum to Breathe: ILD Campaign https://t.co/Yhlw3nGsDh
Links:
Dr. John Cush RheumNow ( View Tweet)
Definitions for Interstitial Lung Disease: A Consensusfrom the Fleischner Society https://t.co/2r9oS1Eb9k https://t.co/GqKq5E0bmp
Dr. John Cush RheumNow ( View Tweet)
Call to Update the Classification Criteria in Idiopathic Inflammatory Myopathies (IMM), Why?
- EULAR/ACR myositis criteria dont cover specific myositis subtypes
- Polymyositis is rare
- antisynthetase & necrotizing myopathy & Jo1 Dz not well represented
- Need to include MSA, https://t.co/P9CEXmEOxl
Dr. John Cush RheumNow ( View Tweet)
SMART study - Single vs. Split Dose Methotrexate in RA
Split dose weekly, oral methotrexate (MTX) was shown to be superior to single dose MTX in treating active rheumatoid arthritis (RA) patients.
https://t.co/K0C63GgHvn https://t.co/FTJ11fpKnB
Dr. John Cush RheumNow ( View Tweet)
Methyl-prednisolone plus methotrexate-based regime vs prednisone-based standard of care for giant cell arteritis: a propensity score study https://t.co/kmLy6NXFO1
Luis Caminal caminalm ( View Tweet)
Optimal glucocorticoid therapy in lupus nephritis
🔓https://t.co/e6SjmOrRpw
➡️This review provides an in-depth analysis of glucocorticoid therapy for lupus nephritis, a severe manifestation of systemic lupus erythematosus that affects up to 51.7% of patients https://t.co/JftCQiFif1
Links:
NDT NDTsocial ( View Tweet)
🎓 Learning just got smarter.
Every week, RheumIQ challenges you with a quick quiz on current rheumatology updates.
💡 Educational
🎯 Evidence-based
🧠 Addictive (in a good way)
Try it now and level up your clinical knowledge: https://t.co/mVZhEpn3lo https://t.co/4cMTZXxsUk
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of urinary soluble CD163 levels in 214 SLE pts (129 w/ LN), found urinary CD163 highly correlates w/ UPCR, active vs inactive states, predicts Renal Bx histologic activity (AUC 0.962) & renal dz flares & allows prediction of complete, partial and non-responders https://t.co/HNKAuFDgPG
Dr. John Cush RheumNow ( View Tweet)
Controversies in ILD
This deep dive into controversies in interstitial lung disease explored complex topics including IPAF, methotrexate, systemic autoimmune rheumatic disease vs. connective tissue disease distinctions, and the evolving role of anti-fibrotic therapy. Panelists: https://t.co/ekP1Gg73yj
Dr. John Cush RheumNow ( View Tweet)
GLP-1 drugs cost-effective for knee osteoarthritis and obesity
A new study led by investigators at Mass General Brigham finds that adding novel weight loss GLP-1 drugs semaglutide and tirzepatide to usual care represents a cost-effective treatment strategy for people with knee https://t.co/pqWDEUgYmI
Dr. John Cush RheumNow ( View Tweet)
